NeuroOne Medical Technologies Corporation(NMTC)Earnings, Financials & Key Ratios
NMTC•NASDAQ
$4.30
$36M mkt cap·Price updated May 6, 2026
AboutNeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.Show more
- Revenue$12M+250.4%
- EBITDA-$4M+65.9%
- Net Income-$4M+70.7%
- EPS (Diluted)-0.54+80.4%
- Gross Margin67.3%+115.2%
- EBITDA Margin-32.77%+90.3%
- Operating Margin-34.94%+89.9%
- Net Margin-29.8%+91.6%
- ROE-91.34%+73.8%
- ROIC-1621.09%+33.3%
- Debt/Equity0.04-88.1%
- Interest Coverage-9.79+81.5%
NMTC Key Insights
NeuroOne Medical Technologies Corporation (NMTC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 23.4%
- ✓Strong 5Y sales CAGR of 44.4%
- ✓Efficient asset utilization: 1.1x turnover
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 50.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NMTC Price & Volume
NeuroOne Medical Technologies Corporation (NMTC) stock price & volume — 10-year historical chart
Loading chart...
NMTC Growth Metrics
NeuroOne Medical Technologies Corporation (NMTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years163.77%
5 Years44.41%
3 Years313.45%
TTM51.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-193.79%
Return on Capital
10 Years-242.78%
5 Years-163.58%
3 Years-157.69%
Last Year-72.62%
NMTC Recent Earnings
NeuroOne Medical Technologies Corporation (NMTC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 17, 2026EPS
$0.03
Est $0.04
+25.0%
Revenue
$3M
Est $3M
+8.9%
Q4 2025
Dec 17, 2025EPS
$0.05
Est $0.04
-25.0%
Revenue
$3M
Est $2M
+9.9%
Q3 2025
Aug 14, 2025EPS
$0.03
Est $0.05
+40.0%
Revenue
$2M
Est $2M
-6.6%
Q2 2025
May 13, 2025EPS
$0.07
Est $0.09
+22.2%
Revenue
$1M
Est $1M
+9.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 17, 2026 | $0.03vs $0.04+25.0% | $3Mvs $3M+8.9% |
| Q4 2025 | Dec 17, 2025 | $0.05vs $0.04-25.0% | $3Mvs $2M+9.9% |
| Q3 2025 | Aug 14, 2025 | $0.03vs $0.05+40.0% | $2Mvs $2M-6.6% |
| Q2 2025 | May 13, 2025 | $0.07vs $0.09+22.2% | $1Mvs $1M+9.4% |
Based on last 12 quarters of dataView full earnings history →
NMTC Peer Comparison
NeuroOne Medical Technologies Corporation (NMTC) competitors in Neuromodulation and neuro devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LIVN | 3.62B | 66.26 | -14.89 | 10.74% | 7.47% | 9.13% | 0.39 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 | |
 BSX | 83.23B | 56.00 | 28.87 | 19.87% | 14.4% | 12.4% | 0.51 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 ITRI | 3.68B | 82.97 | 12.75 | -3.02% | 12.32% | 17.22% | 0.74 | |
 ANIK | 202.62M | 15.12 | -19.89 | -5.91% | -9.52% | -7.74% | 0.17 |
Compare NMTC vs Peers
NeuroOne Medical Technologies Corporation (NMTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NMTC Income Statement
NeuroOne Medical Technologies Corporation (NMTC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 1.93M | 178.15K | 171.17K | 1.95M | 3.45M | 12.1M | 8.72M |
| Revenue Growth % | - | - | - | - | -90.75% | -3.92% | 1040.65% | 76.86% | 250.35% | 51.6% |
| Cost of Goods Sold | 17.63K | 21.67K | 27.57K | 70.55K | 275.89K | 241.96K | 1.5M | 2.37M | 3.96M | 3.93M |
| COGS % of Revenue | - | - | - | 3.66% | 154.87% | 141.36% | 76.62% | 68.73% | 32.7% | - |
| Gross Profit | -17.63K▲ 0% | -21.67K▼ 22.9% | -27.57K▼ 27.2% | 1.86M▲ 6832.2% | -97.75K▼ 105.3% | -70.79K▲ 27.6% | 456.52K▲ 744.9% | 1.08M▲ 136.5% | 8.14M▲ 654.1% | 4.78M▲ 0% |
| Gross Margin % | - | - | - | 96.34% | -54.87% | -41.36% | 23.38% | 31.27% | 67.3% | 54.87% |
| Gross Profit Growth % | -127.82% | -22.88% | -27.24% | 6832.25% | -105.27% | 27.58% | 744.85% | 136.5% | 654.07% | - |
| Operating Expenses | 3.07M | 3.19M | 5.81M | 6.76M | 10.12M | 9.96M | 12.41M | 12.97M | 12.37M | 12.43M |
| OpEx % of Revenue | - | - | - | 350.79% | 5680.99% | 5818.79% | 635.71% | 375.52% | 102.23% | - |
| Selling, General & Admin | 2.34M | 3.54M | 4.28M | 4.75M | 6.26M | 6.98M | 6.93M | 7.9M | 7.38M | 7.23M |
| SG&A % of Revenue | - | - | - | 246.71% | 3514.12% | 4077.5% | 354.75% | 228.84% | 61.04% | - |
| Research & Development | 735.33K | 951.06K | 1.53M | 2.08M | 3.93M | 4.93M | 6.94M | 5.07M | 4.98M | 5.2M |
| R&D % of Revenue | - | - | - | 107.75% | 2203.25% | 2879.86% | 355.49% | 146.69% | 41.19% | - |
| Other Operating Expenses | 0 | -1.3M | 0 | -70.55K | -64.81K | -1.95M | -1.46M | 0 | 0 | 0 |
| Operating Income | -3.07M▲ 0% | -3.21M▼ 4.5% | -5.81M▼ 81.1% | -4.9M▲ 15.7% | -10.22M▼ 108.4% | -10.03M▲ 1.8% | -11.96M▼ 19.2% | -11.89M▲ 0.6% | -4.23M▲ 64.4% | -7.64M▲ 0% |
| Operating Margin % | - | - | - | -254.46% | -5735.86% | -5860.15% | -612.32% | -344.26% | -34.94% | -87.71% |
| Operating Income Growth % | -9321.12% | -4.5% | -81.06% | 15.67% | -108.44% | 1.83% | -19.19% | 0.57% | 64.45% | - |
| EBITDA | -3.05M | -3.19M | -5.79M | -4.83M | -10.07M | -9.91M | -11.76M | -11.64M | -3.96M | -7.38M |
| EBITDA Margin % | - | - | - | -250.79% | -5653.27% | -5790.85% | -602.12% | -337.11% | -32.77% | -84.7% |
| EBITDA Growth % | -12182.13% | -4.4% | -81.43% | 16.49% | -108.44% | 1.58% | -18.6% | 0.98% | 65.94% | -13.02% |
| D&A (Non-Cash Add-back) | 17.63K | 21.67K | 27.57K | 70.55K | 147.13K | 118.62K | 199.27K | 246.79K | 261.68K | 262.07K |
| EBIT | -3.07M | -4.17M | -5.81M | -4.9M | -9.95M | -10.03M | -11.96M | -12.09M | -3.27M | -7.09M |
| Net Interest Income | 0 | 0 | 0 | -7.52M | -3.05K | 0 | 0 | -228.99K | -334.06K | 324.74K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.4M | 0 | 284.56K | 7.52M | 3.05K | 0 | 0 | 228.99K | 334.06K | -324.74K |
| Other Income/Expense | -1.99M | -2.66M | -967.77K | -8.74M | 270.04K | 31.15K | 95.76K | -430.9K | 621.1K | 816.4K |
| Pretax Income | -5.06M▲ 0% | -6.83M▼ 35.0% | -6.78M▲ 0.7% | -13.64M▼ 101.1% | -9.95M▲ 27.1% | -10M▼ 0.5% | -11.86M▼ 18.6% | -12.32M▼ 3.9% | -3.61M▲ 70.7% | -6.83M▲ 0% |
| Pretax Margin % | - | - | - | -708% | -5584.28% | -5841.95% | -607.42% | -356.74% | -29.8% | -78.34% |
| Income Tax | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.06M▲ 0% | -6.83M▼ 35.0% | -6.78M▲ 0.7% | -13.64M▼ 101.1% | -9.95M▲ 27.1% | -10M▼ 0.5% | -11.86M▼ 18.6% | -12.32M▼ 3.9% | -3.61M▲ 70.7% | -6.83M▲ 0% |
| Net Margin % | - | - | - | -708% | -5584.28% | -5841.95% | -607.42% | -356.74% | -29.8% | -78.34% |
| Net Income Growth % | -10488.02% | -34.96% | 0.67% | -101.15% | 27.07% | -0.52% | -18.6% | -3.87% | 70.73% | 5% |
| Net Income (Continuing) | -5.06M | -6.83M | -6.78M | -13.64M | -9.95M | -10M | -11.86M | -12.32M | -3.61M | -6.83M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -13.80▲ 0% | -14.58▼ 5.7% | -10.32▲ 29.2% | -15.12▼ 46.5% | -5.58▲ 63.1% | -3.78▲ 32.3% | -3.90▼ 3.2% | -2.76▲ 29.2% | -0.54▲ 80.4% | -0.81▲ 0% |
| EPS Growth % | -8027.21% | -5.65% | 29.22% | -46.51% | 63.1% | 32.26% | -3.17% | 29.23% | 80.43% | -193.79% |
| EPS (Basic) | -13.80 | -14.58 | -10.32 | -15.12 | -5.58 | -3.78 | -3.90 | -2.76 | -0.54 | - |
| Diluted Shares Outstanding | 367.23K | 467.81K | 658.75K | 902.56K | 1.78M | 2.67M | 3.02M | 4.46M | 6.69M | 8.39M |
| Basic Shares Outstanding | 367.23K | 467.81K | 658.75K | 902.56K | 1.78M | 2.67M | 3.02M | 4.46M | 6.69M | 8.39M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NMTC Balance Sheet
NeuroOne Medical Technologies Corporation (NMTC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 33.61K | 18.64K | 301.75K | 4.16M | 7.29M | 12.18M | 7.31M | 4.63M | 10.23M | 8.07M |
| Cash & Short-Term Investments | 26.47K | 13.26K | 260.75K | 4.04M | 6.9M | 11.14M | 5.32M | 1.46M | 6.57M | 3.56M |
| Cash Only | 26.47K | 13.26K | 260.75K | 4.04M | 6.9M | 8.16M | 5.32M | 1.46M | 6.57M | 3.56M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 2.98M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 48.34K | 33.24K | 0 | 176.64K | 1.26M | 2.66M |
| Days Sales Outstanding | - | - | - | - | 99.03 | 70.87 | - | 18.67 | 38.16 | 44.45 |
| Inventory | 0 | 0 | 0 | 0 | 98.29K | 704.54K | 1.73M | 2.64M | 2.23M | 1.67M |
| Days Inventory Outstanding | - | - | - | - | 130.03 | 1.06K | 421.31 | 405.27 | 205.44 | 176.88 |
| Other Current Assets | 0 | 0 | 0 | 601 | 92.93K | 0 | 0 | 142.63K | 22.92K | 177.45K |
| Total Non-Current Assets | 216.37K | 200.08K | 230.86K | 604.76K | 646.48K | 646.85K | 784.39K | 739.01K | 559.36K | 510.52K |
| Property, Plant & Equipment | 0 | 0 | 52.03K | 448.24K | 512.28K | 534.95K | 694.81K | 671.75K | 514.42K | 471.16K |
| Fixed Asset Turnover | - | - | - | 4.30x | 0.35x | 0.32x | 2.81x | 5.14x | 23.52x | 15.63x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 216.37K | 200.08K | 178.84K | 156.52K | 134.21K | 111.89K | 89.58K | 67.26K | 44.95K | 39.37K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 249.99K▲ 0% | 218.72K▼ 12.5% | 532.62K▲ 143.5% | 4.76M▲ 793.7% | 7.94M▲ 66.8% | 12.82M▲ 61.5% | 8.1M▼ 36.9% | 5.37M▼ 33.7% | 10.79M▲ 100.9% | 8.58M▲ 0% |
| Asset Turnover | - | - | - | 0.40x | 0.02x | 0.01x | 0.24x | 0.64x | 1.12x | 1.01x |
| Asset Growth % | -66.97% | -12.51% | 143.52% | 793.66% | 66.78% | 61.52% | -36.85% | -33.68% | 100.85% | 235.78% |
| Total Current Liabilities | 3.91M | 3.8M | 1.77M | 2.36M | 1.18M | 3.1M | 1.79M | 2.21M | 2.3M | 1.26M |
| Accounts Payable | 0 | 221.24K | 1.15M | 762.54K | 528.83K | 927.66K | 685.1K | 1.03M | 1.01M | 552.33K |
| Days Payables Outstanding | - | 3.73K | 15.26K | 3.94K | 699.62 | 1.4K | 167.16 | 158.28 | 93.21 | 68.22 |
| Short-Term Debt | 2.42M | 1.68M | 0 | 1.01M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 73.43K | 8.62K | 1.46M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.26M | 512.39K | 50.4K | 166.3K | 0 | 0 | 0 | 59.95K | 1.44K | 0 |
| Current Ratio | 0.01x | 0.00x | 0.17x | 1.76x | 6.17x | 3.93x | 4.08x | 2.09x | 4.44x | 4.44x |
| Quick Ratio | 0.01x | 0.00x | 0.17x | 1.76x | 6.09x | 3.70x | 3.12x | 0.90x | 3.47x | 3.47x |
| Cash Conversion Cycle | - | - | - | - | -470.56 | -265.71 | - | 265.65 | 150.39 | 153.1 |
| Total Non-Current Liabilities | 1.38M | 817.15K | 0 | 337.66K | 202.9K | 119.56K | 55.28K | 2.33M | 1.41M | 917.23K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 254.33K | 202.9K | 119.56K | 55.28K | 194.39K | 143.15K | 635.84K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.38M | 817.15K | 0 | 83.33K | 0 | 0 | 0 | 2.14M | 1.27M | 4.48M |
| Total Liabilities | 5.29M | 4.61M | 1.77M | 2.69M | 1.38M | 3.22M | 1.85M | 4.55M | 3.71M | 2.18M |
| Total Debt | 2.42M | 1.68M | 0 | 1.32M | 315.67K | 202.9K | 184.4K | 260.16K | 266.81K | 237.38K |
| Net Debt | 2.39M | 1.66M | -260.75K | -2.72M | -6.59M | -7.96M | -5.14M | -1.2M | -6.3M | -3.32M |
| Debt / Equity | - | - | - | 0.64x | 0.05x | 0.02x | 0.03x | 0.32x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.45x |
| Interest Coverage | -2.20x | - | -20.43x | -0.65x | -3257.49x | - | - | -52.79x | -9.79x | 21.83x |
| Total Equity | -5.04M▲ 0% | -4.4M▲ 12.7% | -1.24M▲ 71.8% | 2.07M▲ 267.0% | 6.55M▲ 217.2% | 9.6M▲ 46.5% | 6.25M▼ 34.9% | 822.01K▼ 86.8% | 7.07M▲ 760.4% | 6.4M▲ 0% |
| Equity Growth % | -1791.9% | 12.72% | 71.85% | 266.95% | 217.2% | 46.54% | -34.93% | -86.85% | 760.39% | 979.22% |
| Book Value per Share | -13.72 | -9.40 | -1.88 | 2.29 | 3.68 | 3.60 | 2.07 | 0.18 | 1.06 | 0.76 |
| Total Shareholders' Equity | -5.04M | -4.4M | -1.24M | 2.07M | 6.55M | 9.6M | 6.25M | 822.01K | 7.07M | 6.4M |
| Common Stock | 7.87K | 9.66K | 13.49K | 22.18K | 12.01K | 16.22K | 23.93K | 30.82K | 50.01K | 50.41K |
| Retained Earnings | -5.32M | -10.46M | -17.24M | -30.88M | -40.83M | -50.83M | -62.69M | -75M | -78.61M | -80.05M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NMTC Cash Flow Statement
NeuroOne Medical Technologies Corporation (NMTC) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.11M | -2.83M | -5.4M | -3.43M | -8.6M | -7.52M | -12.89M | -11.01M | -3.14M | -2.84M |
| Operating CF Margin % | - | - | - | -177.79% | -4829.09% | -4393.05% | -660.04% | -318.91% | -25.92% | - |
| Operating CF Growth % | -9888.03% | -34.13% | -90.83% | 36.52% | -151.16% | 12.59% | -71.38% | 14.55% | 71.53% | -1419.44% |
| Net Income | -5.06M | -6.76M | -6.78M | -13.64M | -9.95M | -10M | -11.86M | -12.32M | -3.61M | -6.83M |
| Depreciation & Amortization | 17.63K | 20.56K | 27.57K | 47.61K | 80.75K | 118.62K | 199.27K | 246.79K | 261.68K | 262.07K |
| Stock-Based Compensation | 76.79K | 486.12K | 491.75K | 1.84M | 1.79M | 947.21K | 1.11M | 1.34M | 1.26M | 1.28M |
| Deferred Taxes | 590.97K | 0 | 683.21K | 2.02M | -85.31K | -11.47K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2M | 3.42M | 284.56K | 6.74M | 69.44K | 212.16K | 96.4K | 669.61K | -626.94K | -485.62K |
| Working Capital Changes | 859.89K | 1.77K | -101.88K | -429.56K | -512.73K | 1.21M | -2.43M | -954.61K | -429.19K | -393.66K |
| Change in Receivables | 0 | 0 | 0 | 0 | -48.34K | 15.1K | 33.24K | -176.64K | -1.09M | -292.95K |
| Change in Inventory | 0 | 0 | 0 | 0 | -98.29K | -606.25K | -1.02M | -908.47K | 398.35K | 254.71K |
| Change in Payables | 0 | 0 | 770.61K | -269.6K | -350.31K | 515.44K | -247.19K | 66.99K | 239.98K | -185.07K |
| Cash from Investing | -91.71K | -146.71K | -123.35K | -122.43K | -67.08K | -3.24M | 2.65M | -120.2K | -81.74K | -98.08K |
| Capital Expenditures | -91.71K | 0 | -123.35K | -122.43K | -67.08K | -275.23K | -384.12K | -120.2K | -81.74K | -98.08K |
| CapEx % of Revenue | - | - | - | 6.35% | 37.65% | 160.79% | 19.67% | 3.48% | 0.68% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 2.97M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -91.71K | -146.71K | -65K | 0 | 0 | -2.97M | 7.5K | 0 | 0 | 0 |
| Cash from Financing | 1.7M | 2.92M | 5.77M | 7.32M | 11.53M | 12.02M | 7.4M | 7.27M | 8.33M | 8.69M |
| Debt Issued (Net) | 954.13K | 0 | -283K | 8.44M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 4.56M | 390K | 8.83M | 13.35M | 8.47M | 5.79M | 8.33M | 159.09K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -119.42K | -81.4K | -124.62K | -116.98K |
| Other Financing | 749.9K | 2.92M | 1.49M | -1.51M | 2.71M | -1.33M | -1.07M | 1.48M | 0 | 8.53M |
| Net Change in Cash | -495.75K▲ 0% | -56.77K▲ 88.5% | 247.49K▲ 536.0% | 3.78M▲ 1425.6% | 2.86M▼ 24.1% | 1.26M▼ 56.1% | -2.84M▼ 325.4% | -3.86M▼ 36.1% | 5.11M▲ 232.3% | 2.43M▲ 0% |
| Free Cash Flow | -2.2M▲ 0% | -2.83M▼ 28.5% | -5.52M▼ 95.2% | -3.55M▲ 35.7% | -8.67M▼ 144.4% | -7.79M▲ 10.1% | -13.27M▼ 70.3% | -11.13M▲ 16.1% | -2.92M▲ 73.8% | -6.26M▲ 0% |
| FCF Margin % | - | - | - | -184.15% | -4866.74% | -4553.84% | -679.71% | -322.39% | -24.13% | -71.81% |
| FCF Growth % | -10322.54% | -28.54% | -95.19% | 35.72% | -144.38% | 10.09% | -70.26% | 16.12% | 73.78% | 11.87% |
| FCF per Share | -5.99 | -6.04 | -8.38 | -3.93 | -4.86 | -2.92 | -4.39 | -2.50 | -0.44 | -0.44 |
| FCF Conversion (FCF/Net Income) | 0.42x | 0.41x | 0.80x | 0.25x | 0.86x | 0.75x | 1.09x | 0.89x | 0.87x | 0.92x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NMTC Key Ratios
NeuroOne Medical Technologies Corporation (NMTC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -3292.36% | -230.81% | -123.77% | -149.61% | -348.39% | -91.34% | -119.92% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -931.56% | -650.16% | -2431.11% | -1621.09% | -1621.09% |
| Gross Margin | - | - | - | 96.34% | -54.87% | -41.36% | 23.38% | 31.27% | 67.3% | 54.87% |
| Net Margin | - | - | - | -708% | -5584.28% | -5841.95% | -607.42% | -356.74% | -29.8% | -78.34% |
| Debt / Equity | - | - | - | 0.64x | 0.05x | 0.02x | 0.03x | 0.32x | 0.04x | 0.04x |
| Interest Coverage | -2.20x | - | -20.43x | -0.65x | -3257.49x | - | - | -52.79x | -9.79x | 21.83x |
| FCF Conversion | 0.42x | 0.41x | 0.80x | 0.25x | 0.86x | 0.75x | 1.09x | 0.89x | 0.87x | 0.92x |
| Revenue Growth | - | - | - | - | -90.75% | -3.92% | 1040.65% | 76.86% | 250.35% | 51.6% |
NMTC Frequently Asked Questions
NeuroOne Medical Technologies Corporation (NMTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NeuroOne Medical Technologies Corporation (NMTC) reported $8.7M in revenue for fiscal year 2025. This represents a 746786% increase from $0.0M in 2010.
NeuroOne Medical Technologies Corporation (NMTC) grew revenue by 250.4% over the past year. This is strong growth.
NeuroOne Medical Technologies Corporation (NMTC) reported a net loss of $6.8M for fiscal year 2025.
Dividend & Returns
NeuroOne Medical Technologies Corporation (NMTC) has a return on equity (ROE) of -91.3%. Negative ROE indicates the company is unprofitable.
NeuroOne Medical Technologies Corporation (NMTC) had negative free cash flow of $6.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More NMTC
NeuroOne Medical Technologies Corporation (NMTC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates